Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme (NASDAQ: HALO) named David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay will oversee all financial operations while the company continues its search for a permanent CFO.
He brings more than 30 years of biotech financial leadership and previously served as Halozyme CFO from 2003–2009 and 2013–2015. Halozyme has engaged a leading executive search firm to identify a permanent CFO; Ramsay will remain until an appointment is made.
Halozyme (NASDAQ: HALO) announced that Johnson & Johnson received U.S. FDA approval (March 6, 2026) for TECVAYLI (teclistamab) combined with DARZALEX FASPRO for adults with relapsed/refractory multiple myeloma after ≥1 prior therapy. The approval followed Phase 3 MajesTEC-3 data showing statistically significant PFS and OS benefits.
Key trial results: hazard ratio 0.17 for progression or death (95% CI 0.12–0.23; P<0.0001) and a three-year PFS rate of 83% after median three-year follow-up.
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will present and hold investor meetings at three upcoming conferences: TD Cowen on March 3, 2026, Leerink on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026.
Live audio webcasts will be available on the company investor relations website, with replays accessible for 90 days after each event.
Halozyme (NASDAQ: HALO) reported record full‑year 2025 total revenue of $1.397 billion, driven by $867.8 million in royalties (+52% YoY). The company completed acquisitions of Elektrofi (Hypercon) and Surf Bio, issued convertible notes, and reiterated 2026 guidance: $1.71–$1.81B revenue, $1.125–$1.205B adjusted EBITDA, and $7.75–$8.25 non‑GAAP EPS.
Net income was $316.9M (includes $284.9M acquired IPR&D); cash and equivalents declined to $145.4M.
Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.
According to the company, a conference call to discuss results will be held on February 17, 2026 at 1:30pm PT / 4:30pm ET, with live webcast and replay available via Halozyme's Investors website.
Halozyme (Nasdaq: HALO) raised its outlook after strong 2025 momentum, updating preliminary 2025 revenue to $1,385–$1,400M (36–38% YoY) and royalty revenue to $865–$870M (51–52% YoY). For 2026 the company raised guidance to $1,710–$1,810M total revenue and $1,130–$1,170M royalties, with adjusted EBITDA of $1,125–$1,205M and non-GAAP EPS of $7.75–$8.25. Halozyme acquired Surf Bio for an upfront $300M (up to $400M total) to add hyperconcentration technology enabling formulations up to 500 mg/mL.
Nootropics Depot (HALO) corrected its Sept. 16, 2025 release to report that its High Potency Saffron Extract capsules are standardized to 7.5% crocins and 1% safranals, claiming the highest measured concentrations among tested supplements.
Independent and ISO‑accredited HPLC testing reportedly shows the product contains 1.97x more crocins and 1.18x more safranal per capsule versus the next competitor; manufacturing occurs in cGMP and FDA‑registered facilities in Arizona, with batch COAs publicly available.
Halozyme (NASDAQ: HALO) will host an investor conference call on Wednesday, January 28, 2026 at 5:30 AM PT / 8:30 AM ET. Management led by Dr. Helen Torley, President and CEO, and Nicole LaBrosse, CFO, will provide preliminary unaudited full-year 2025 revenue results, updated 2026–2028 financial guidance, and a business update. The call requires pre-registration and will be webcast live via the Investors section of Halozyme.com, with presentation materials available 15 minutes before the call and a recording posted after the call.
Halozyme (NASDAQ: HALO) announced a global collaboration and exclusive license agreement with Takeda (signed December 2025) to provide access to Halozyme's ENHANZE® rHuPH20 drug delivery technology for use with vedolizumab (marketed as ENTYVIO).
Under the agreement, Takeda will make an upfront payment to Halozyme, potential future development and commercial milestone payments, and Halozyme may receive up to low-mid single digit royalties on sales of vedolizumab combined with ENHANZE®. Vedolizumab is approved for IV and SC administration in various markets for adults with moderately to severely active Crohn's disease or ulcerative colitis.
Halozyme (NASDAQ: HALO) announced that the U.S. FDA approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) co-formulated with ENHANZE for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer on Dec 18, 2025. RYBREVANT FASPRO™ is approved across all RYBREVANT indications and is the first and only subcutaneous targeted therapy for EGFR+ mNSCLC.
Compared with IV delivery, administration time fell to ~5 minutes and administration-related reactions declined ~fivefold (13% SC vs 66% IV). The product met both co-primary PK endpoints in Phase 3 PALOMA-3 (Ctrough at C2D1 or C4D1 and C2 AUC D1-D15). Johnson & Johnson issued related press details on Dec 17, 2025.